Delcasertib is a selective inhibitor of delta-protein kinase C ( delta-PKC ) , which reduced infarct size during ischaemia/reperfusion in animal models and diminished myocardial necrosis and improved reperfusion in a pilot study during primary percutaneous coronary intervention ( PCI ) for ST elevation myocardial infarction ( STEMI ) .